Compare NEGG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEGG | CDXS |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 141.8M |
| IPO Year | 2010 | 2010 |
| Metric | NEGG | CDXS |
|---|---|---|
| Price | $54.71 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 146.9K | ★ 1.1M |
| Earning Date | 12-01-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,313,127,000.00 | $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $1.52 |
| 52 Week High | $137.84 | $5.51 |
| Indicator | NEGG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 42.82 |
| Support Level | $53.32 | $1.61 |
| Resistance Level | $59.21 | $1.75 |
| Average True Range (ATR) | 5.06 | 0.09 |
| MACD | -1.64 | 0.01 |
| Stochastic Oscillator | 8.39 | 18.57 |
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.